中国实用内科杂志2024，Vol.44Issue(10)：810-816,7.DOI:10.19538/j.nk2024100104
1型发作性睡病的免疫治疗进展
Immunotherapy advances for type 1 narcolepsy
摘要
Abstract
Narcolepsy,a rare sleep disorder,is divided into type 1 and type 2,with type 1 distinguished by the significant loss of hypocretin-secreting neurons in the hypothalamus.Significant advancements have been made in the past two decades in understanding the autoimmune mechanisms and genetic predispositions of narcolepsy,particularly its strong linkage with HLA-DQB1*06:02 and other non-HLA immune genes.Present treatment modalities focus primarily on symptom manag-ement,whilst trials in immunotherapy are emergently being explored aiming to modulate immune responses and diminish attacks on hypocretin-producing neurons,thereby addressing the etiology of the condition.Treatment avenues such as intravenous immunoglobulin,corticosteroids,and monoclonal antibodies have demonstrated potential therapeutic promise;however,most are derived from case reports,and their long-term efficacy remains to be further investigated in comprehensive studies.关键词
1型发作性睡病/下丘脑分泌素/免疫疗法Key words
type 1 narcolepsy/hypocretin/immunotherapy分类
医药卫生引用本文复制引用
张慧敏,詹淑琴..1型发作性睡病的免疫治疗进展[J].中国实用内科杂志,2024,44(10):810-816,7.基金项目
国家自然科学基金(82371489) （82371489）
国家重点研发计划项目(2021YFC2501400) （2021YFC2501400）
